Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea;Ertapénem intraveineux ou sous-cutané pour le traitement des infections urinaires à entérobactérie sécrétrice de BLSE

Medecine et Maladies Infectieuses

Volumn 42, Issue 9, 2012, Pages 440-443

  Forestier, E ^a   Gros, S ^a   Peynaud, D ^a   Levast, M ^a   Boisseau, D ^a   Ferry Blanco, C ^a   Labe, A ^a   Lecomte, C ^a   Rogeaux, O ^a  

^a CENTRE HOSPITALIER DE CHAMBÉRY   (France)

Author keywords

Ertapenem; ESBL enterobacteriacea; Urinary tract infection

Indexed keywords

ERTAPENEM;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CYSTITIS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; ENTEROBACTERIACEAE; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; OUTCOME ASSESSMENT; OUTPATIENT CARE; PROSTATITIS; PYELONEPHRITIS; RETROSPECTIVE STUDY; URINALYSIS; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CYSTITIS; DRUG EVALUATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; PROSTATITIS; PYELONEPHRITIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84866758022     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2012.07.005     Document Type: Article

References (12)

1. Prakash V., Lewis J.S., Herrera M.L., Wickes B.L., Jorgensen J.H. Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2009, 53:1278-1280.
2. Tomera K.M., Burdmann E.A., Reyna O.G., Jiang Q., Wimmer W.M., Woods G.L., et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002, 46:2895-2900.
3. Wells W.G., Woods G.L., Jiang Q., Gesser R.M. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004, 53(Suppl. 2):ii67-ii74.
4. Bazaz R., Chapman A.L., Winstanley T.G. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J Antimicrob Chemother 2010, 65:1510-1513.
5. Dalgic N., Sancar M., Bayraktar B., Dincer E., Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis 2011, 43:339-343.
6. Frasca D., Marchand S., Petitpas F., Dahyot-Fizelier C., Couet W., Mimoz O. Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. Antimicrob Agents Chemother 2010, 54:924-926.
7. Robelet A., Caruba T., Corvol A., Begue D., Gisselbrecht M., Saint-Jean O., et al. Antibiotics given subcutaneously to elderly. Presse Med 2009, 38:366-376.
8. Remington R., Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence. J Am Geriatr Soc 2007, 55:2051-2055.
9. Hoban D.J., Nicolle L.E., Hawser S., Bouchillon S., Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011, 70:507-511.
10. Hsueh P.R., Hoban D.J., Carmeli Y., Chen S.Y., Desikan S., Alejandria M., et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect 2011, 63:114-123.
11. Zhanel G.G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D.J., et al. Comparative review of the carbapenems. Drugs 2007, 67:1027-1052.
12. Nicolau D.P., Carmeli Y., Crank C.W., Goff D.A., Graber C.J., Lima A.L., et al. Carbapenem stewardship: does ertapenem affect pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents 2012, 39:11-15.